Getinge (OTCMKTS:GNGBY) Reaches New 1-Year High – Still a Buy?

Getinge (OTCMKTS:GNGBY) reached a new 52-week high during trading on Tuesday. The stock traded as high as $27.0525 and last traded at $26.8510, with a volume of 357 shares trading hands. The stock had previously closed at $26.82.

Analyst Ratings Changes

A number of brokerages have recently commented on GNGBY. Pareto Securities cut Getinge from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 24th. Nordea Equity Research cut Getinge from a “buy” rating to a “hold” rating in a research note on Monday, August 31st. Zacks Research downgraded Getinge from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 17th. Finally, UBS Group assumed coverage on shares of Getinge in a research note on Wednesday, September 2nd. They issued a “hold” rating for the company. Four investment analysts have rated the stock with a Hold rating. Based on data from MarketBeat, the stock presently has an average rating of “Hold”.

Getinge Price Performance

The company has a market capitalization of $7.31 billion, a price-to-earnings ratio of 24.41 and a beta of 0.95. The company has a quick ratio of 0.74, a current ratio of 1.31 and a debt-to-equity ratio of 0.26. The business has a 50-day moving average price of $25.24 and a two-hundred day moving average price of $22.55.

Getinge (OTCMKTS:GNGBY) last issued its quarterly earnings data on Wednesday, October 21st. The company reported $0.32 earnings per share (EPS) for the quarter. Getinge had a net margin of 8.20% and a return on equity of 11.55%. The business had revenue of $875.58 million during the quarter. As a group, research analysts anticipate that Getinge will post 1.38 EPS for the current year.

About Getinge

Getinge AB is a Sweden-based medical technology company that develops products and solutions for hospitals, healthcare providers and life sciences organizations. Its offerings are designed to support patient care, surgical procedures, infection prevention and the development and production of pharmaceuticals and other medical products.

The company’s portfolio includes equipment for intensive care and cardiovascular procedures, operating-room systems, surgical instruments, sterilization and disinfection solutions, and products used in laboratories and biopharmaceutical manufacturing.